New Consumer Survey Discovers Many Misconceptions About Heart Health

More than 100 million Americans suffer from chronic conditions, like heart disease and diabetes, according to the National Health Council. As the leading cause of death in the United States, heart disease has spurred numerous initiatives, like the Centers for Disease Control (CDC) and Center for Medicare and Medicaid Services (CMS) creating the Million Hearts 2022 campaign to reduce the number of heart attacks by the year 2022.

Despite many great efforts aimed at spreading awareness and improving the state of heart health in the U.S., our recent consumer survey found that 71 percent of Americans incorrectly selected drug use, cancer, gun violence, vehicular accidents or other factors as the leading killers of Americans. Why the disconnect? The answer may be fear.

We found that 37 percent of people have avoided seeing a doctor over the fear of diagnosis, and the top dread of those who do see a doctor (30 percent) regarding cardiac care is misdiagnosis or missed diagnosis. These concerns are not unreasonable. However, if you are at risk of heart disease, the best course of action is to talk to your physician to address any issues before they get worse.

Below are suggested questions that the American Heart Association recommends you ask your physician:

If you are at risk for heart disease, your doctor may suggest things like weight loss or gain, more physical activity, a healthy diet, getting more sleep or a consultation with a specialist.

Remember, your health is your own. The more you know and the more you communicate your concerns with a doctor, the better your chances of having a heart-healthy future.

To read more about heart disease, click here. If you’re interested in learning more about HeartFlow and the HeartFlow Analysis, click here.

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.